Biotechnology firm Amgen Inc. (NASDAQ: AMGN) on Tuesday reported higher revenues and adjusted earnings for the third quarter of 2023. The company
Amgen Inc.
-(AMGN)
XNAS:AMGN
AMGN Earnings: Everything you need to know about Amgen’s Q2 results
Amgen Inc. (NASDAQ: AMGN) on Friday reported higher revenues and adjusted earnings for the second quarter of 2023. The biotechnology firm also
AMGN Earnings: Everything you need to know about Amgen’s Q1 results
Amgen Inc. (NASDAQ: AMGN) has reported lower revenues and adjusted earnings for the first quarter of 2023. The biotechnology firm also provided
Amgen Inc. (AMGN) Q1 2023 Earnings Call Transcript
Amgen Inc. (NASDAQ: AMGN) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Arvind Sood — Vice President, Investor Relations Robert A. Bradway — Chairman
Amgen Inc (AMGN) Q4 2022 Earnings Call Transcript
Amgen Inc (NASDAQ:AMGN) Q4 2022 Earnings Call dated Jan. 31, 2023. Corporate Participants: Arvind Sood -- Vice President, Investor Relations Robert A. Bradway -- Chairman
AMGN Infographic: Amgen’s Q4 2022 profit drops on flat revenues
Amgen Inc. (NASDAQ: AMGN) said its revenues remained unchanged in the fourth quarter of 2022 when the biotechnology firm's earnings declined. Unadjusted
Amgen Inc (AMGN) Q3 2022 Earnings Call Transcript
Amgen Inc (NASDAQ:AMGN) Q3 2022 Earnings Call dated Nov. 03, 2022. Corporate Participants: Arvind Sood -- Vice President of Investor Relations Bob Bradway -- Chairman &
Amgen Inc. (AMGN) Q2 2022 Earnings Call Transcript
Amgen Inc. (NASDAQ: AMGN) Q2 2022 earnings call dated Aug. 04, 2022 Corporate Participants: Arvind Sood -- Vice President, Investor Relations Robert A. Bradway -- Chairman
Earnings calendar for the week of August 2
Labor market conditions improved once again and jobless claims dropped to about 400,000 after rising last week, as economic activity picked up.
Amgen Inc. (AMGN) Q1 2021 Earnings Call Transcript
Amgen Inc. (NASDAQ: AMGN) Q1 2021 earnings call dated Apr. 27, 2021 Corporate Participants: Arvind Sood -- Vice President, Investor Relations Robert A. Bradway -- Chairman
Here’s what you need to know before investing in Amgen (AMGN)
The coronavirus outbreak has made leading pharma companies channelize their resources for vaccine development, and the efforts have been largely successful. While
Amgen Inc (AMGN) Q4 2020 Earnings Call Transcript
Amgen Inc (NASDAQ: AMGN) Q4 2020 earnings call dated Feb. 02, 2021. Corporate Participants: Arvind Sood -- Vice President, Investor Relations Robert A. Bradway -- Chairman
Earnings calendar for the week of February 1
In a week that saw one of the worst stock selloffs, Gamestop came under spotlight after the stock experienced unprecedented fluctuations, marked
Earnings calendar for the week of January 11
Stock markets responded positively to the latest developments in presidential election. On the heels of the Dow Jones Industrial Average achieving a
Amgen Inc. (AMGN) Q3 2020 Earnings Call Transcript
Amgen Inc. (NASDAQ: AMGN) Q3 2020 earnings call dated Oct. 28, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A. Bradway -- Chairman
Amgen Inc. (AMGN) Q2 2020 Earnings Call Transcript
Amgen Inc (NASDAQ: AMGN) Q2 2020 earnings call dated July 28, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A.
Amgen Inc (NASDAQ: AMGN) Q1 2020 Earnings Call Transcript
Amgen Inc (AMGN) Q1 2020 earnings call dated Apr. 30, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A. Bradway -- Chairman
A visual dashboard of Amgen’s (AMGN) Q1 2020 earnings results
Amgen's (NASDAQ: AMGN) top and bottom line in the first quarter of 2020 beat analysts' estimates. The biotech firm's adjusted earnings per
Amgen Inc (NASDAQ: AMGN) Q4 2019 Earnings Call Transcript
Amgen Inc (NASDAQ: AMGN) Q4 2019 Earnings Conference Call January 30, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A. Bradway -- Chairman
Amgen beats in Q3, raises guidance
Amgen Inc (NASDAQ: AMGN) reported third-quarter 2019 adjusted EPS of $3.66 on revenue of $5.74 billion. This was better than analysts’ prediction
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction.